Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (NEO-AEGIS): an open-label, randomised, phase 3 trial.
Reynolds JV, Preston SR, O’Neill B, Lowery MA, Baeksgaard L, Crosby T et al, on behalf of the Neo-AEGIS Investigators and trial group.
Lancet Gastrohepatol 2023; 8: 1015-1027.
Some 362 patients were available for analysis after a median of 38.8 months. Overall survival was 48 months after perioperative chemotherapy versus 49.2 months after trimodality therapy; hazard ratio 1.03, 95 per cent confidence interval 0.77 to 1.38; P=0.82.
Comment: Disappointing result, and calls into question the role of radiotherapy for this condition.
24 January 2024
Read paperAcademy
Part of the charitable activity of the Foundation, BJS Academy is an online educational resource for current and future surgeons.
The Academy is comprised of five distinct sections: Continuing surgical education, Young BJS, Cutting edge, Scientific surgery and Surgical news. Although the majority of this is open access, additional content is available to BJS subscribers and strategic partners.
